Up-to-date information for this session is displayed below.
select
Tuesday, February 23, 2010
TimePresentationSpeakers
7:55 AMWelcome & Introduction
H. Bryan Brewer, MD (Speaker)
Steven E. Nissen, MD (Speaker)
8:00 AMHow do we Reduce Residual Risk in High Risk Patients After Statin Therapy?
Christie M. Ballantyne, MD (Speaker)
8:15 AMIs HDL Therapy Hype or the Future Blockbuster Treatment for CVD Patients?
Ernst J. Schaefer, MD (Speaker)
8:30 AMSelective Increase in ApoA-I Synthesis: Update on a Novel Approach to Increase HDL
Norman C. W. Wong, MD (Speaker)
8:45 AMAcute HDL Therapy: Update on HDL Infusion Therapy in the ACS Patient
H. Bryan Brewer, MD (Speaker)
9:00 AMIs There Dysfunctional HDL? How do we Test HDL Function?
Sergio Fazio, MD, PhD (Speaker)
9:15 AMCurrent Status of Anacetrapib: A Second Generation CETP Inhibitor to Raise HDL
Yale B. Mitchel, MD (Speaker)
9:30 AMUpdate on Clinical Trials with Dalcetrapib: A Second Generation CETP Inhibitor
David G. Kallend, MD (Speaker)
9:45 AMPanel Discussion
Christie M. Ballantyne, MD (Panelist)
H. Bryan Brewer, MD (Moderator)
Sergio Fazio, MD, PhD (Panelist)
David G. Kallend, MD (Panelist)
Yale B. Mitchel, MD (Panelist)
Ron Waksman, MD (Panelist)
Norman C. W. Wong, MD (Panelist)
10:15 AMBreak
10:30 AMDEBATE - Identification of the Vulnerable Plaque: Critical Concept
James E. Muller, MD (Speaker)
10:40 AMDEBATE - Identification of the Vulnerable Plaque: Hype?
Steven E. Nissen, MD (Speaker)
10:50 AMDEBATE - Identification of the Vulnerable Plaque: Critical Concept or Hype? - DISCUSSION
James E. Muller, MD (Speaker)
Steven E. Nissen, MD (Speaker)
11:00 AMUpdate on the Clinical Development of Nicotinic Acid/Laropiprant, a New Agent to Reduce the Side Effects of Niacin
Yale B. Mitchel, MD (Speaker)
11:15 AMCurrent Status of Darapladib: A New Selective Inhibitor of LpPLA2 to Decrease Atherosclerosis
Robert L. Wilensky, MD (Speaker)
11:30 AMSecretory Phospholipase A2: A Multifaceted Proatherogenic Family of Enzymes
Robert S. Rosenson, MD (Speaker)
11:45 AMIs it Time to Screen the Asymptomatic Patient for Cardiovascular Disease?
Allen J. Taylor, MD (Speaker)
12:00 PMLunch and Visit the Exhibits
1:00 PMMRI of the Ischemic Area at Risk, Myocardial Infarction and Myocardial Salvage
Andrew E. Arai, MD (Speaker)
1:15 PMShould hCRP be Included in the new Cardiovascular Guidelines?
Paul M. Ridker, MD (Speaker)
1:30 PMShould Anti-inflammatory Drugs be the Next Target for the Treatment of the CVD Patient?
Jean-Claude Tardif, MD (Speaker)
1:45 PMWhat Should be the Lipid Targets in Patients with Diabetes and the Metabolic Syndrome?
Michael H. Davidson, MD (Speaker)
2:00 PMShould we Move from Lipoproteins to Apolipoproteins in Future Guidelines for CVD?
Allan D. Sniderman, MD (Speaker)
2:15 PMPanel Discussion
Andrew E. Arai, MD (Panelist)
Michael H. Davidson, MD (Panelist)
Steven E. Nissen, MD (Moderator)
Paul M. Ridker, MD (Panelist)
Allan D. Sniderman, MD (Panelist)
Jean-Claude Tardif, MD (Panelist)
Allen J. Taylor, MD (Panelist)
2:45 PMThe Future of Imaging as a Surrogate in the Development of new Cardiovascular Drugs
Stephen J. Nicholls, MD, PhD (Speaker)
3:00 PMChallenges Facing Lipid Guidelines
Peter W. F. Wilson, MD (Speaker)
3:15 PMDoes the Practicing Cardiologist Need to Assess LDL and HDL Subclasses in the Treatment of Cardiovascular Disease Patients?
Peter O. Kwiterovich, MD (Speaker)
3:30 PMCIMT: a Useful Surrogate for Assessing the Efficacy of new Cardiovascular Drugs?
Daniel H. O'Leary, MD (Speaker)
3:45 PMThe Role of Cardiac CT in CHD Risk Stratification
Guy Weigold, MD (Speaker)
4:00 PMPanel Discussion
Peter O. Kwiterovich, MD (Panelist)
Stephen J. Nicholls, MD, PhD (Panelist)
Steven E. Nissen, MD (Moderator)
Daniel H. O'Leary, MD (Panelist)
Guy Weigold, MD (Panelist)
Peter W. F. Wilson, MD (Panelist)
4:15 PMClosing Remarks
Steven E. Nissen, MD (Speaker)
4:30 PMAdjourn